Biotechnology firm Vasa Therapeutics announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead investigational compound, VS‑041, which is being developed to treat Heart Failure with Preserved Ejection Fraction (HFpEF). The Fast Track designation gives Vasa enhanced regulatory interaction, potential rolling submission of a future New Drug Application (NDA), and eligibility for priority review, underlining the unmet medical need in HFpEF and Vasa’s biomarker‑driven approach.
According to Vasa, the small‑molecule inhibitor targets matrix metalloproteinases MMP‑2 and MMP‑9, aiming to interfere with the fibroinflammatory processes underpinning heart‑muscle stiffening and impaired relaxation in HFpEF (a condition affecting approximately 3 million U.S. and 10 million globally).
The company said that in preclinical models of HFpEF, VS‑041 reduced fibrosis and improved diastolic function, and completed a Phase 1 study in healthy participants, showing acceptable safety and tolerability. Vasa also disclosed that an Investigational New Drug (IND) application was cleared by the FDA for a Phase 1c “proof‑of‑mechanism” trial enrolling HFpEF patients with elevated serum endotrophin, a biomarker associated with poor outcomes.
While the milestone marks a positive regulatory signal, the therapeutic remains early in clinical development and will need to demonstrate efficacy and safety in HFpEF patients to fulfil its promise.
